{
  "docId": "019de075-8a55-750a-8008-603750933d71",
  "docSlug": "da8608bdf4ad385699d1340db7dce185",
  "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
  "authorId": "erasca",
  "authorName": "Erasca",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 43,
  "pageCount": 56,
  "prevPage": 42,
  "nextPage": 44,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-8a55-750a-8008-603750933d71/43",
  "deckHref": "/decks/019de075-8a55-750a-8008-603750933d71",
  "deckJsonHref": "/decks/019de075-8a55-750a-8008-603750933d71.json",
  "deckAnchorHref": "/decks/019de075-8a55-750a-8008-603750933d71#slide-43",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.12,
        "x": 0.86,
        "y": 0.9
      },
      "kind": "image",
      "text": "ERASCA",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "66b23b0c-2dd1-45a6-ab66-d2b3c32109d8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.88,
        "x": 0.057,
        "y": 0.64
      },
      "kind": "list",
      "text": "FOUR CLINICAL-STAGE COMPOUNDS: Differentiated profiles including naporafenib, a pivotal-ready pan-RAF inhibitor for NRASm melanoma and Q61X tissue agnostic solid tumors, ERAS-007 ERKi, ERAS-601 SHP2i, and ERAS-801, a CNS-penetrant EGFRi for GBM",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6c0ef1c1-224b-459a-8f7e-f57c5ff1b35e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.88,
        "x": 0.057,
        "y": 0.8
      },
      "kind": "list",
      "text": "MULTIPLE POTENTIAL NEAR-TERM AND LONG-TERM VALUE DRIVERS: Focused clinical development plan with multiple combination and monotherapy readouts in 2023 and beyond and a strong research engine to drive best-in-class compounds into the clinic",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6dfda000-6fb6-4023-94fc-50c7a901960e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.88,
        "x": 0.057,
        "y": 0.32
      },
      "kind": "list",
      "text": "WORLD-CLASS SCIENTIFIC ADVISORY BOARD: Leading pioneers in KRAS (Shokat, UCSF), SHP2 (Blacklow, HMS), ERK (Corcoran, MGH), RAS/MAPK pathway (Rodriguez-Viciana, UCL; Cichowski, HMS), precision oncology (Demetri, DFCI), and biopharma (Varney, Genentech)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "846a6226-ade4-47ba-aa19-3eda67b19f3e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.88,
        "x": 0.057,
        "y": 0.48
      },
      "kind": "list",
      "text": "BROAD PORTFOLIO TO ERASE CANCER: We believe we have built the deepest pipeline in the industry to comprehensively shut down RAS/MAPK pathway, with the potential to address unmet needs in over 5 million patients globally",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "af11f7c1-33d3-4c9e-b017-97ae01c8fd6f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.88,
        "x": 0.057,
        "y": 0.00117
      },
      "kind": "list",
      "text": "EXPERIENCED TEAM WITH TRACK RECORD OF SERIAL SUCCESSES: Seasoned drug developers who have advanced multiple programs from discovery to IND to global approvals",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "df8b812b-e7d7-4079-906e-4af83e63bf1c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.382,
        "x": 0.027,
        "y": 0.045
      },
      "kind": "title",
      "text": "Compelling investment thesis",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cf31d9c2-3f31-4c3b-b03c-b7c2503912d7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "a259123f-45c1-4ac1-a30b-775b6ff52072",
      "evidence": "Compelling investment thesis",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 44,
      "from": 42,
      "beatId": "a69b3bd5-ee9f-43e1-8899-1c300b6881b2",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "The document outlines Erasca's anticipated key milestones and clinical trial readouts.",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 44,
      "from": 42,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "4f36a34d-ac49-471d-8a8d-29994cfbabb4",
      "evidence": "The document outlines Erasca's anticipated key milestones and clinical trial readouts.",
      "position": 1,
      "objective": "What are the potential quick wins and big bets for Erasca's pipeline?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}